Page last updated: 2024-09-03

icrf 193 and Leukemia

icrf 193 has been researched along with Leukemia in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ando, J; Ando, M; Isobe, Y; Oshimi, K; Sasaki, M; Sugimoto, K; Suto, H; Tamayose, K; Tsutsui, M	1

Other Studies

1 other study(ies) available for icrf 193 and Leukemia

Article	Year
Hsp90-inhibitor geldanamycin abrogates G2 arrest in p53-negative leukemia cell lines through the depletion of Chk1. Oncogene, 2008, May-15, Volume: 27, Issue:22 Topics: Antibiotics, Antineoplastic; Benzoquinones; Cell Death; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Diketopiperazines; DNA Damage; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; G2 Phase; Genes, p53; HeLa Cells; HL-60 Cells; HSP90 Heat-Shock Proteins; Humans; Jurkat Cells; Lactams, Macrocyclic; Leukemia; Piperazines; Protein Kinases	2008

Article

Year

Hsp90-inhibitor geldanamycin abrogates G2 arrest in p53-negative leukemia cell lines through the depletion of Chk1.

Oncogene, 2008, May-15, Volume: 27, Issue:22

Topics: Antibiotics, Antineoplastic; Benzoquinones; Cell Death; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Diketopiperazines; DNA Damage; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; G2 Phase; Genes, p53; HeLa Cells; HL-60 Cells; HSP90 Heat-Shock Proteins; Humans; Jurkat Cells; Lactams, Macrocyclic; Leukemia; Piperazines; Protein Kinases

2008